Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

lCept in the treatment of autoimmune indications and any future products for our targeting indications may be greater than anticipated; the risk that we may not sustain our profitability; our ability to attract and retain collaborations relating to the development and commercialization of new indications; competition from other pharmaceutical or biotechnology companies; our ability to raise additional financing required to fund further research and development, clinical studies, and obtain regulatory approvals, on commercially acceptable terms or at all; economic and capital market conditions; our ability to obtain and protect patents and other intellectual property rights; our ability to operate without infringing the intellectual property rights of others; our ability to comply with applicable governmental regulations and standards; currency exchange rates; and our ability to successfully attract and retain skilled and experienced personnel.

For a more thorough discussion of the risks associated with Aspreva's business, see the "Risk Factors" section in Aspreva's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed with the U.S. Securities and Exchange Commission at http://www.sec.gov and with securities regulatory authorities in Canada at http://www.sedar.com. Although we have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Aspreva undertakes no obligation to revise or update any forward-looking statements as a result of n
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:11/26/2014)... , Nov. 26, 2014  Aethlon Medical, Inc. ... definitive agreement to raise approximately $3.3 million at a ... made by one institutional healthcare focused investor. Each unit consists ... a common share purchase warrant. Each whole warrant entitles ... price of $0.30 for a period of five years ...
(Date:11/26/2014)...   Regulus Therapeutics Inc . (NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... of Regulus, will present a company overview at the ... the New York Palace Hotel on Wednesday, December 3, ... webcast at the time of the presentation and can ...
(Date:11/26/2014)... -- BioScrip ® , Inc. (NASDAQ: BIOS ) announced today ... will present at the Bank of America Merrill Lynch 2014 Leveraged ... , , , Wednesday, December 3, 2014 , , , ... , , Location: , , , Boca Raton Resort and Club, ... BioScrip, Inc. is a leading national provider of ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3
... -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... in the development, manufacturing, and marketing of branded and ... Mr. Hong Zhao, a highly regarded executive in the ... sales and marketing, effective February 12, 2011. ...
... Calif., Feb. 10, 2011 Renaissance Surgical Arts at Newport ... center in the Western United States to offer intraoperative radiotherapy ... in the TARGIT-A multicenter human clinical trial that demonstrated IORT ... with early breast cancer. IORT has the ...
Cached Medicine Technology:Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 3
(Date:11/27/2014)... Ethane Web Technologies, which is an ... reputation management service. , The company has designed ... world of internet marketing and algorithms of major search ... Web Technologies does not work with the same strategy ... to reach a conclusion what will work for the ...
(Date:11/27/2014)... 2014 VeloReality Inc. President Gary ... Life Videos (RLVs) of world-famous velo courses for the company's ... as other popular indoor velo trainers. Two dozen additional Real ... the end of November -- in time for the ... of rides in the VeloReality collection to over sixty. , ...
(Date:11/27/2014)... November 27, 2014 Serious Buyer, Andrew ... 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum concert posters. Between ... played at the University of Alabama. Jimi Hendrix started ... Hawley, “It started with Gary Weinberger who was a ... University Programs Council. The council was responsible for bringing ...
(Date:11/26/2014)... CA (PRWEB) November 26, 2014 Dr. ... treat themselves this holiday season! With Parsa Mohebi Hair ... 10% off of their next FUE procedure, making it ... , FUE—which stands for “Follicular Unit Extraction”—is an advanced ... over traditional “strip” Follicular Unit Transplantation (FUT). FUE, unlike ...
(Date:11/26/2014)... 27, 2014 Sweetdressy.com, the well-known wedding ... newest selection of cheap prom dresses for ladies worldwide. ... The prom dresses from Sweetdressy.com are very popular in ... the website of Sweetdressy.com now. , Sweetdressy.com believes ... that offering the best items and best services. The ...
Breaking Medicine News(10 mins):Health News:Ethane Web Technologies Announces Online Reputation Management Service 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3Health News:Serious Buyer Announces His Search For Vintage 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum Concert Posters 2Health News:FUE Special at Parsa Mohebi Hair Restoration This Holiday Season 2Health News:Cheap Prom Dresses For Ladies Introduced At SweetDressy.com 2
... May 8 (HealthDay News) -- People at risk for celiac ... they show no symptoms, a new study suggests. Celiac ... small intestine when the person consumes gluten, a protein found ... with the disease has grown rapidly in recent decades, but, ...
... , MONDAY, May 9 (HealthDay News) -- Some ... emotional reactions to everyday situations, a combination that appears ... a Massachusetts General Hospital study that included 83 participants ... deficient emotional self-regulation (DESR), 33 with neither condition -- ...
... of U.S. children taken to hospital emergency departments (EDs) for ... ease worried parents, concerns. Yet true traumatic brain injury is ... minor blunt head trauma, led by Children,s Hospital Boston and ... reduce the use of head CT by as much as ...
... UK,s betting shops are attracting a new type of ... terms of problem gambling, argues initial research findings funded ... Betting shops today are virtually unrecognisable compared to the ... Act. "Under the Act, the newly licensed betting offices ...
... -- (May 9, 2011) In the wild, mammals survive ... shadowy bushes. That ability translates to the human ... in an image of our messy and stuffed suitcases. We ... our car keys on that cluttered shelf next to the ...
... patient without common symptoms of celiac disease is accurately ... study from the Beth Israel Deaconess Medical Center in ... divided the cases of nearly 800 adult patients with ... per capita earnings. Some patients had complained of acute ...
Cached Medicine News:Health News:More People May Benefit From Going Gluten-Free 2Health News:ADHD With Poor Emotional Control Seems to Run in Families 2Health News:Large study finds CT scans are frequently unnecessary after head injury in children 2Health News:Large study finds CT scans are frequently unnecessary after head injury in children 3Health News:50 years on, UK betting shops lure new breed of punters 2Health News:The brain performs visual search near optimally 2
... Korchek Technologies CareChek ... employs barcode technology, Windows ... with integrated scanners (to ... at the bedside) and ...
... Korchek Technologies CareChek Rx ... barcode technology, Windows CE ... integrated scanners (to perform ... the bedside) and an ...
... care management tools that support the nursing ... vital signs and I&O information at the ... on-line flow sheets. This design supports compliance ... the hall, or at the nursing station, ...
For superior bar code scanning performance with maximum user comfort at a highly attractive price, the LS 4000i Scanner Series from Symbol Technologies establishes an award-winning standard of excell...
Medicine Products: